文献速递抗栓抗凝管理

更高最大剂量和输注速率相比标准普通肝素治疗与肥胖及非肥胖心血管患者充分抗凝且不增加出血相关

Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
PubMed 文献 · Pharmacotherapy · 2017-03-10

回顾性队列研究纳入197例因NSTEMI/UA、房颤或其他心脏适应症接受连续普通肝素(UFH)输注至少6小时的成人患者,比较标准剂量策略(71例)与激进剂量策略(126例)达标活化部分凝血活酶时间(aPTT)及出血情况。激进策略组6小时内达标aPTT比例显著更高(23% vs 11%,p=0.043),两组均无出血事件。

要点

  • 激进剂量策略6小时内aPTT达标率显著高于标准剂量(23% vs 11%,p=0.043)。
  • 两组超治疗范围aPTT及最高aPTT值无显著差异(p=0.817和p=0.348)。
  • 两组均未报告出血事件,激进剂量可用于肥胖及非肥胖患者。

核心结论

  • 采用更高UFH最大团注剂量和输注速率的患者更快达到治疗性抗凝且不增加出血,剂量可针对肥胖及非肥胖患者调整。
  • 尽管使用更高剂量,仅23%患者在6小时内达到治疗性aPTT,提示可能需要更高的团注剂量和输注速率。

研究设计与样本

  • 回顾性队列研究,纳入197例因NSTEMI/UA、房颤或其他心脏适应症接受连续UFH输注至少6小时的成人患者。
  • 标准剂量组71例(2013年9月至2014年2月):60单位/kg团注(最大4000单位)后12单位/kg/小时输注(最大1000单位/小时)。
  • 激进剂量组126例(2014年10月至2015年3月):60单位/kg团注(最大10000单位)后12单位/kg/小时输注(最大2250单位/小时)。

主要发现

  • 激进策略组6小时内达到治疗性aPTT(60-80秒)的比例显著高于标准剂量组(23% vs 11%,p=0.043)。
  • 标准剂量组肥胖患者延迟或未能达到治疗性抗凝尤为明显。
  • 初始输注速率均值±标准差:标准剂量组10.8±1.4单位/kg/小时,激进策略组12±0.02单位/kg/小时(p=<0.0005)。
  • 两组超治疗范围aPTT发生率(p=0.817)和最高aPTT值(p=0.348)相似。
  • 两组均未报告出血事件。

关键数值与推荐

  • 治疗性aPTT范围定义为60-80秒。
  • 标准剂量策略:60单位/kg团注(最大4000单位)后12单位/kg/小时输注(最大1000单位/小时)。
  • 激进剂量策略:60单位/kg团注(最大10000单位)后12单位/kg/小时输注(最大2250单位/小时)。

临床怎么用

  • 对肥胖及非肥胖心血管适应症患者,可采用更高最大团注剂量和输注速率的UFH策略以更快达到治疗性抗凝。
  • 即使采用激进剂量,6小时内aPTT达标率仍仅23%,需密切监测aPTT并考虑进一步调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: To evaluate the time to achieve therapeutic activated partial thromboplastin time (aPTT) values and occurrence of bleeding based on standard unfractionated heparin (UFH) weight-based dosing recommendations compared with an aggressive weight-based UFH dosing strategy using higher maximum doses and infusion rates in both obese and nonobese patients who presented with non-ST-segment elevation myocardial infarction or unstable angina (NSTEMI/UA) or atrial fibrillation. DESIGN: Retrospective cohort study. SETTING: Academic medical center. PATIENTS: A total of 197 adults were included who were admitted for NSTEMI/UA, atrial fibrillation, or other cardiac indications and received at least 6 hours of a continuous UFH infusion. Of those patients, 71 were treated with standard UFH dosing (60-unit/kg bolus [or maximum 4000 units] followed by an infusion of 12 units/kg/hour [or maximum 1000 units/hr]) between September 2013 and February 2014, and 126 patients received an aggressive UFH dosing strategy (60-unit/kg bolus [or maximum 10,000 units] followed by an infusion of 12 units/kg/hr [or maximum 2250 units/hr]) between October 2014 and March 2015. Patients in the standard dosing and aggressive strategy cohorts were further classified by body mass index status (normal, overweight, obese, and morbidly obese) and weight status. MEASUREMENTS AND MAIN RESULTS: A time-to-event analysis for achievement of therapeutic aPTT range (60-80 sec) was assessed. A significantly higher proportion of patients treated with the aggressive strategy achieved a therapeutic aPTT within 6 hours (23% vs 11%, p=0.043). The delay or failure to achieve therapeutic anticoagulation was particularly evident in obese patients in the standard dosing group. The mean ± SD initial infusion rate was 10.8 ± 1.4 units/kg/hour in the standard dosing group versus 12 ± 0.02 units/kg/hour in the aggressive strategy group (p=<0.0005). The occurrence of supratherapeutic aPTT values and the highest aPTT achieved were similar between the two dosing groups (p=0.817 and p=0.348, respectively). No bleeding events were reported in either group. CONCLUSION: Patients who had higher UFH maximum bolus doses and infusion rates achieved therapeutic anticoagulation more rapidly, without increased bleeding, and these doses can be adjusted for obese as well as nonobese patients. However, despite use of the higher doses, only 23% of patients achieved therapeutic aPTT values within 6 hours, suggesting that an even higher bolus dose and infusion rate may still be warranted.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Floroff CK, Palm NM, Steinberg DH, et al. Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications. Pharmacotherapy. 2017. PMID: 28107569. doi:10.1002/phar.1904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。